92-1

92-1细胞92-1细胞92-1；人葡萄膜黑色素瘤细胞

Cell line name 92-1 [Human uveal melanoma]

Synonyms 92_1; 92.1; 921

Accession CVCL_8607

Resource Identification Initiative To cite this cell line use: 92-1 [Human uveal melanoma] (RRID:CVCL_8607)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Doubling time: 58 hours (PubMed=7622289); 38 hours (PubMed=24994677).

Omics: Deep quantitative proteome analysis.

Omics: Transcriptome analysis by microarray.

Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.

Sequence variations

Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=22236444; PubMed=22383533; PubMed=23851445; PubMed=24994677; PubMed=28018010).

HLA typing Source: PubMed=28018010

Class I

HLA-A A*02:01,03:01

HLA-B B*44:02,51:01

HLA-C C*05:01,14:02

Disease Uveal melanoma (NCIt: C7712)

Uveal melanoma (ORDO: Orphanet_39044)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_C4PP (92.1-A) CVCL_C4PQ (92.1-B)

Originate from same individual CVCL_C300 ! 92-2

Sex of cell Female

Age at sampling 76Y

Category Cancer cell line

STR profile Source(s): DepMap=ACH-001441; ECACC=13012458; ESTDAB=ESTDAB-127; PubMed=22236444; PubMed=24994677; PubMed=28018010

 

Markers:

Amelogenin X

CSF1PO 10,11

D3S1358 14,15

D5S818 9,11 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444; PubMed=24994677)

12,13 (ESTDAB=ESTDAB-127)

D7S820 10,11 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444; PubMed=24994677)

11 (ESTDAB=ESTDAB-127)

D8S1179 15

D13S317 10,11 (ESTDAB=ESTDAB-127; PubMed=24994677)

11,12 (DepMap=ACH-001441; ECACC=13012458; PubMed=22236444)

D16S539 11,12 (PubMed=22236444; PubMed=24994677)

12 (DepMap=ACH-001441; ECACC=13012458)

D18S51 12,13

D21S11 30

FGA 21,23

Penta D 9,11

Penta E 12,14

TH01 9,9.3

TPOX 8,9

vWA 16

 

Run an STR similarity search on this cell line

Publications

PubMed=7622289; DOI=10.1002/ijc.2910620208

De Waard-Siebinga I., Blom D.-J.R., Griffioen M., Schrier P.I., Hoogendoorn E., Beverstock G.C., Danen E.H.J., Jager M.J.

Establishment and characterization of an uveal-melanoma cell line.

Int. J. Cancer 62:155-161(1995)

 

PubMed=15714118; DOI=10.1097/00008390-200502000-00006

Lopez-Velasco R., Morilla-Grasa A., Saornil-Alvarez M.A., Ordonez J.L., Blanco G., Rabano G., Fernandez N., Almaraz A.

Efficacy of five human melanocytic cell lines in experimental rabbit choroidal melanoma.

Melanoma Res. 15:29-37(2005)

 

PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016

White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.

Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.

Cancer Genet. Cytogenet. 168:11-21(2006)

 

PubMed=17487557; DOI=10.1007/s10585-007-9072-z

Marshall J.-C., Nantel A., Blanco P., Ash J., Cruess S.R., Burnier M.N. Jr.

Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis.

Clin. Exp. Metastasis 24:353-362(2007)

 

PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131

Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T., Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.

Cancer Immunol. Immunother. 58:1507-1515(2009)

 

PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x; PMCID=PMC3288394

Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K., Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.

Genetic and molecular characterization of uveal melanoma cell lines.

Pigment Cell Melanoma Res. 25:182-187(2012)

 

PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676

Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V., Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M., Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.

Mol. Cancer Ther. 11:888-897(2012)

 

PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011

Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I., Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R., Salvi S., Truini M., Poggi A., Pfeffer U.

Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by gefitinib and cetuximab triggered antibody-dependent cellular cytotoxicity.

Eur. J. Cancer 49:3353-3365(2013)

 

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006

Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.

Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.

Mol. Cancer Res. 11:1166-1178(2013)

 

PubMed=24994677; DOI=10.1016/j.molonc.2014.06.004; PMCID=PMC5528590

Amirouchene-Angelozzi N., Nemati F., Gentien D., Nicolas A., Dumont A., Carita G., Camonis J., Desjardins L., Cassoux N., Piperno-Neumann S., Mariani P., Sastre-Garau X., Decaudin D., Roman-Roman S.

Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Mol. Oncol. 8:1508-1520(2014)

 

PubMed=28018010; PMCID=PMC5161001

Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.

Uveal melanoma cell lines: where do they come from? (an American Ophthalmological Society thesis).

Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016)

 

PubMed=32430489; DOI=10.1158/1535-7163.MCT-19-1016; PMCID=PMC7415561

Teh J.L.F., Purwin T.J., Han A., Chua V., Patel P., Baqai U., Liao C., Bechtel N., Sato T., Davies M.A., Aguirre-Ghiso J.A., Aplin A.E.

Metabolic adaptations to MEK and CDK4/6 cotargeting in uveal melanoma.

Mol. Cancer Ther. 19:1719-1726(2020)

 

PubMed=36164296; DOI=10.1016/j.dib.2022.108592; PMCID=PMC9508510

Fei X.-F., Xie X.-T., Ji X.-Y., Tian H.-Y., Sun F., Jiang D.-Y., Wang Z.-M., Huang Q.

Quantitative proteomic dataset of whole protein in three melanoma samples of 92.1, 92.1-A and 92.1-B.

Data Brief 45:108592.1-108592.7(2022)